![Servier - Moved by you..]({"type":"image" , "src" : "/sda/112354/JournalAd-Servier-5s.gif"})
References
- Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, Gibson CM1. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019–25.
- Spaulding C, Morice MC, Lancelin B, El Haddad SE, Lep-age E, Bataille S, Tresca JP, Mouranche X, Fosse S, Monchi M, de Vernejoul N, for the CARDIO-ARIF reg-istry Investigators. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. Eur Heart J 2006; 27: 1054–60.
- Van de Werf F. Fine tuning the selection of a reperfusion strategy. Circulation 2006; 114: 2002–3.
- Amstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary inter-vention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J2006; 27: 1530–8.
- Pitt B, Waters D, Brown WV, van Boven Ad, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin Versus Revascularization Treatment Inves-tigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6.
- Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Har-ris CL, Chaitman B, Shaw L, Gosselin G, Nawaz S, Title L, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GBJ, Weintraub WS, for the COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503–16.
- Waters D. Is a mechanical or a metabolic approach supe-rior in the treatment of coronary disease? Results of the atorvastatin versus revascularisation (AVERT) trial. Eur Heart J2000; 21: 1029–31.
![A worldwide pioneer in biotechnology.]({"type":"image" , "src" : "/sda/112403/JournalAd-Amgen-MPU.png"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})